Virios Therapeutics Announces Second Quarter 2024 Financial Results
August 08, 2024 09:15 ET
|
Virios Therapeutics
- Bateman Horne Center completed enrollment in its groundbreaking investigator-initiated Long-COVID phase 2a study featuring valacyclovir and celecoxib (IMC-2) - - Top-line results from the Bateman...
Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center
July 23, 2024 09:15 ET
|
Virios Therapeutics
- Virios projects releasing top line results from this groundbreaking Proof of Concept study in October 2024 - - Published data indicates increased Epstein-Barr herpes virus in Long-COVID patients,...
Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
May 22, 2024 13:30 ET
|
Virios Therapeutics
ATLANTA, May 22, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company” or “Virios Therapeutics”), a development-stage biotechnology company focused on advancing novel...
Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
May 17, 2024 16:10 ET
|
Virios Therapeutics
ATLANTA, May 17, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company” or “Virios Therapeutics”), a development-stage biotechnology company focused on advancing novel...
Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024 07:45 ET
|
Virios Therapeutics
- Top-line results from the ongoing investigator-initiated Bateman Horne Center Long-COVID phase 2 featuring valacyclovir and celecoxib (IMC-2) expected in the second-half of 2024 - - Conference Call...
Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID
March 26, 2024 09:15 ET
|
Virios Therapeutics
- New patent would extend coverage and expand potential value of Virios’ antiviral pipeline globally – - Active Long-COVID characterized by immune dysfunction leading to recurrent herpesviruses...
Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
February 29, 2024 09:15 ET
|
Virios Therapeutics
ATLANTA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat...
Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID
January 22, 2024 09:00 ET
|
Virios Therapeutics
- Placebo-Controlled Clinical Proof of Concept Data Expected in Mid-2024 -- Targeting Initiation of IMC-2 Phase 2 program in 2H 2024 - ATLANTA, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Virios...
Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID
January 02, 2024 07:05 ET
|
Virios Therapeutics
ATLANTA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on developing novel antiviral therapies to...